Oxford scientists expect COVID-19 vaccine data by Christmas

Oxford is developing its vaccine in conjunction with the drugmaker AstraZeneca

Vaccine
Last week, Moderna had quoted its interim data of late-stage clinical trial to affirm that its experimental vaccine was 94.1 per cent effective in preventing COVID-19. | Pic for representational purpose

University of Oxford scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas, a key researcher said on Thursday as he discussed the teams latest findings.

Dr Andrew Pollard, an expert in pediatric infection and immunity at Oxford, said research was slowed by low infection rates over the summer, but the Phase III trials are now accumulating the data needed to report results as a renewed surge of the pandemic hits countries around the world. Oxford is developing its vaccine in conjunction with the drugmaker AstraZeneca.

I think were getting close, and its definitely going to be before Christmas based on the progress, Pollard said in an interview with the BBC.

Two other drugmakers, Pfizer and Moderna, this week reported preliminary results from late-stage trials showing that their COVID-19 vaccines were almost 95% effective.

Pollard said there is no competition between the various research teams, because several vaccines will be needed to bring the global pandemic under control and allow life to return to normal.

Despite recent progress, Pollard said the world is still in the early stages of the effort to protect people against COVID-19. Even after vaccines are approved by regulators, drugmakers and public health officials still face the task of producing billions of doses and administering them to people around the world, he said.

Pollard, an amateur mountaineer, compared the task to the work involved in climbing a mountain.

“I think we’re still at the bottom of that mountain in some ways, he said. We’ve done the route into the bottom of the mountain, the long trek to get to the start. Now we’ve got to get the data about the vaccines in front of regulators for them to scrutinise it and approve the first vaccines. And then we’ve got that huge effort to climb up to the top where we’ve got a vast majority of those who are at risk vaccinated.”


(Except for the headline, this story has not been edited by The Federal staff and is auto-published from a syndicated feed.)

Get breaking news and latest updates from India
and around the world on thefederal.com
FOLLOW US: